December 4, 2020
San Antonio Breast Cancer Symposium 2020, Tempus-authored — Background: Breast cancer demonstrates heterogeneity in biological features, and the therapeutic strategy depends on tumor subtype. African-Ancestry (AA) patients experience a disproportionally high rate of triple negative breast cancer (TNBC) and worse outcomes than European-Ancestry (EA) patients. However, the biological drivers causing this...
December 4, 2020
San Antonio Breast Cancer 2020, Tempus-authored — Background: In patients with early breast cancer, neoadjuvant therapy is widely performed as standard of care. While the molecular targeting strategy makes progress in HER2 positive breast cancer, the optimal regimens for ER+/HER2- breast cancer (BC) and triple negative breast cancer (TNBC...
December 4, 2020
San Antonio Breast Cancer Symposium, Tempus-authored — Genomic testing has transformed clinical care in metastatic breast cancer. Cell-free DNA (cfDNA) has made sequential testing feasible, however, concordance between tissue and cfDNA, sensitivity of cfDNA, and optimal sampling frequency have not been examined on large data sets with clinical annotation....
August 11, 2020
medRxiv, Tempus-authored — We performed a retrospective analysis of longitudinal real-world data (RWD) from breast cancer patients to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular subtypes. PATIENTS AND...
June 11, 2020
Journal of Cutaneous Pathology, Tempus-authored — Deep penetrating nevi (DPN) are dermal‐based, heavily pigmented melanocytic proliferations primarily resulting from mutations in B‐catenin and BRAF or, less commonly, NRAS. DPNs are considered to be intermediate grade tumors which are stable with low risk of malignant tra...
May 15, 2020
American Association for Cancer Research Annual Meeting 2020, Tempus-authored — Background: We recently reported two ESR1 fusions (ESR1-YAP1 and ESR1-PCDH11X) that drive endocrine therapy (ET) resistance and metastasis in estrogen receptor positive (ER+) metastatic breast cancer (MBC) (PMC6171747). Here we report additional ESR1 fusions wit...
May 15, 2020
American Association for Cancer Research Annual Meeting 2020, Tempus-authored — Early detection of recurrence is critical to improve the survival of cancer patients. Blood-based “liquid biopsies” provide a minimally invasive method to detect variants, and ultra low-pass whole-genome sequencing (LPWGS) can accurately and sensitively detect low fractions of circulating tumor...
May 15, 2020
American Association for Cancer Research Annual Meeting 2020, Tempus-authored — Background: Patient derived tumor organoids (TOs) are emerging as potential models to elucidate mechanisms of tumor biology and therapeutic response. Here, we establish pan-cancer metrics for validation of genetic and transcriptomic recapitulation, and concordance of an organoid to its native tumor...
May 15, 2020
American Association for Cancer Research Annual Meeting 2020, Tempus-authored — Background: Tumors of unknown origin account for up to 5% of newly diagnosed cancers and the average survival time is 9 to 12 months from diagnosis. Establishing tumor type and subtype guides standard of care treatment for several NCCN targeted therapy guidelines. Metho...
May 15, 2020
American Association for Cancer Research Annual Meeting 2020, Tempus-authored — Gene fusions can serve as key drivers in the development of various cancers and represent important therapeutic targets and diagnostic biomarkers. Due to high detection of candidate fusions from RNA-sequencing data, there is a recognized need to build tools that...